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Síntese e Atividade Biológica de Ésteres do Borneol 
Resumo: Ésteres do borneol têm sido considerados como promissores agentes anti-
inflamatórios e antimicrobianos. Neste trabalho, oito ésteres do borneol (1-8) foram 
sintetizados utilizando o método DIC/DMAP ou SOCl2 e os produtos caracterizados por meio de 
técnicas espectroscópicas. Seis desses compostos são inéditos e o método DIC/CMAP foi mais 
rápido e resultou em rendimentos de reação elevados. Os compostos 1-8 foram submetidos ao 
ensaio antiproliferativo in vitro utilizando linhagens de células normais e tumorais e à 
avaliação da atividade antiedematogênica. O composto 6 [(1S,2R,4S)-1,7,7-
trimetilbiciclo[2.2.1]heptan-2-il 3,4,5-trimetoxibenzoato] apresentou promissora atividade 
citotóxica contra várias linhagens de células tumorais e 7 [(1S,2R,4S)-1,7,7-
trimetilbiciclo[2.2.1]heptan-2-il benzoato] foi efetivo na redução da  resposta edematogênica 
em todos os períodos de tempo avaliados. 
Palavras-chave: Ésteres do borneol; atividade antiproliferativa; atividade antiedematogênica. 
 
Abstract 
Borneol derivatives have been regarded as promising anti-inflammatory and antimicrobial 
agents. In this work, eight borneol esters (1-8) were synthesized using DIC/DMAP or SOCl2 
method and the products characterized by means of spectroscopic techniques. Six of them are 
new compounds and the DIC/DMAP method was faster and resulted in high reaction yields. 
Compounds 1-8 were subjected to in vitro antiproliferative assay using normal and tumor 
human cell lines and to antioedematogenic activity evaluation. Compound 6 [(1S,2R,4S)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl 3,4,5-trimethoxybenzoate] presented a promisor cytotoxic 
activity against various tumor cell lines and 7 [(1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-
2-yl benzoate] was effective in the reduction of oedematogenic response in all period of time 
evaluated. 
Keywords: Borneol ester; antiproliferative activity; antioedematogenic activity. 
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1. Introduction 
 
Borneol, a bicyclic monoterpenoid 
alcohol, is used in food, cosmetics and also in 
the traditional medicine to treat painful and 
inflammatory conditions.1 This natural 
product is frequently found as constituent of 
essential oils from numerous families of 
plants (e.g, Asteraceae, Lamiaceae, 
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Valerianaceae and others).2 The essential oil 
of Ampelopsis megalophylla a species of the 
Vitaceae family was analyzed by GC-MS and 
presented borneol as the major constituent 
(10.8%).3 Furthermore, two cinnamic esters 
of borneol were identified for the first time 
in Cistus genus.4  
Previous investigation of borneol and its 
ester derivatives have showed their 
antimicrobial and anti-inflammatory 
properties.5,6 Caffeic acid bornyl ester was 
previously isolated from the chloroform 
extract of Valeriana wallichii rhizome and 
presented antileishmanial activity. Other 27 
borneol derivatives were synthesized and the 
cinnamic acid bornyl ester showed the best 
activity against Leishmania major and 
Leishmania donovani promastigotes (IC50= 
39.6 and 15.6 µM, respectively) with 
cytotoxicity in acceptable levels.7 
Antitrypanosomal activity was reported 
for two synthetic borneol derivatives: 
trimethoxy-benzoate and benzoate bornyl 
ester. These compounds presented an 
antiproliferative effect on the epimastigote 
forms of the parasite Trypanosoma cruzi 
(IC50/72h= 28.9 and 49.5 µM, respectively) and 
both compounds were more selective against 
epimastigotes than HEp-2 cells. Thus, bornyl 
benzoate derivatives can be a potential 
chemotherapeutic agents against T. cruzi 
infections.5 
Bornyl salicylate is another example of 
borneol derivative that presents anti-
inflammatory effect in topical use. Recent 
study evaluated the effect of bornyl salicylate 
in experimental models of acute 
inflammation and signs of acute toxicity were 
not observed in male and female mice. 
Moreover, treatment with bornyl salicylate 
was effective in the reduction of paw edema 
in early and late phases, suggesting an anti-
inflammatory effect related with the 
decrease of pro-inflammatory mediators.6 In 
a recent report was described the synthesis 
of some natural product esters with 
improved biological activity.8 Keeping this in 
mind, the present work aimed to synthesize 
eight borneol ester derivatives and evaluate 
their antiproliferative and antioedematogenic 
properties, that were not described yet. 
 
2. Experimental 
 
2.1. Chemistry 
 
2.1.1. Materials and methods 
 
Commercially reagent grade chemicals 
were used as received without additional 
purification. (-)-Borneol was purchased at 
95% purity from Sigma-Aldrich. All reactions 
were monitored by thin layer 
chromatography (TLC) processes. Column 
chromatographic purifications were 
performed using silica gel 60 (70–230 Mesh). 
The IR spectra were carried out on a Perkin 
Elmer – Spectrum One (ATR, 4000-400 cm-1) 
spectrometer. The 1H and 13C spectra were 
recorded on a Bruker AVANCE DPX-200 
spectrometry at 200 and 50 MHz, 
respectively, using CDCl3 as solvent. Chemical 
shifts are reported in parts per million (δ 
ppm) using tetramethylsilane (TMS) as 
internal standard. Melting points were 
determined on a Microquímica MQAPF 301 
hot plate apparatus and are uncorrected. 
 
2.1.2. Synthesis of borneol ester 
derivatives using DIC/DMAP 
 
(–)-Borneol (1 mmol) and the appropriate 
organic acid (5 mmol) with catalytic amount 
of 4-dimethylaminopyridine (DMAP) were 
dissolved in dichloromethane (6 mL) and 
cooled in an ice bath. The mixture was stirred 
for an additional 10 min and then 
diisopropylcarbodiimide (DIC) (5 mmol) was 
added. The mixture was removed from the 
ice bath and was magnetically stirred at room 
temperature until esterification was 
complete.9 The progress of the reaction was 
monitored by TLC using as eluent a mixture 
of chloroform and n-hexane in different 
proportions. After finishing, the reaction 
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mixture was evaporated in vacuum to 
dryness. The residue was purified by means 
of column chromatography on silica gel using 
hexane/chloroform (1:1, V/V) as eluent. All 
the synthesized compounds were oils, 
except 6 and 8, which were solids.   
 
2.1.3. Synthesis of borneol ester 
derivatives using SOCl2 
 
A solution of 2.0 mL (27.5 mmol) of 
thionyl chloride and 1 mmol of each acid 
were added in a round bottom flask. After 
heating the reaction mixture for 3 h in reflux, 
thionyl chloride excess was removed under 
vacuum. The remaining residue was dissolved 
in toluene (2 mL) and 1 mmol of (–)-borneol 
was added. This mixture was stirred in reflux 
and the reaction was monitored by TLC using 
as eluent a mixture of chloroform and n-
hexane in different proportions. NaHCO3 
aqueous solution (5%) was slowly added 
when the reaction was finished. This last 
mixture was extracted with chloroform (3× 
25 mL) and the organic phase was washed 
again with 30 mL of NaHCO3 aqueous 
solution (5%) and then with water (2× 20 mL). 
The organic phases were pooled and dried 
with anhydrous NaSO4. Organic solvent was 
removed using a rotary evaporator and the 
residue was purified by silica gel column 
chromatographic using as eluent a mixture of 
chloroform and n-hexane in different 
proportions. 
 
2.2. Biological activities 
 
2.2.1. Antiproliferative assay 
 
The human cancer cell lines MCF-7 
(human breast adenocarcinoma), NCI-
ADR/RES (drug resistant ovarian tumor), 786-
0 (renal cell adenocarcinoma), OVCAR-3 
(human ovarian carcinoma), HT-29 (colon 
adenocarcinoma), K562 (leukemia) were 
kindly provided by Frederick Cancer Research 
& Development Center–National Cancer 
Institute–Frederick, MA, USA. HaCat cell line 
(immortalized human keratinocytes) was 
kindly donated by Dr. Ricardo Della Coletta, 
FOP–Unicamp.  
Stock cell cultures were grown in medium 
containing RPMI 1640, supplemented with 
5% fetal bovine serum. Experimental cultures 
were supplemented also with 
peŶiĐiliŶe:streptoŵiĐiŶe ;ϭϬ μg/ŵL:ϭϬ 
UI/ŵLͿ. Cells ;ϭϬϬ μL Đells/ǁell, iŶoĐulatioŶ 
density from 3-6 x 104 cell/mL) in 96-well 
microtiter plates were exposed to different 
sample concentrations ;Ϭ.Ϯϱ to ϮϱϬ μg/ŵL, 
ϭϬϬ μL/ǁellͿ iŶ DMSO/RPMI ϭϲϰϬ at ϯϳ oC, 
5% of CO2 in air during 48 h. DMSO final 
ĐoŶĐeŶtratioŶs ;≤ Ϭ.Ϯϱ%Ϳ iŶ Đulture ŵediuŵ 
did not affect cell viability. Cells were fixed 
with 50% trichloroacetic acid and cell 
proliferation was evaluated by 
spectrophotometric quantification (540 nm) 
of cellular protein content, by means of 
sulforhodamine B assay. Doxorubicin (DOX) 
(0.025-Ϯϱ μg/ŵLͿ ǁas used as positiǀe 
control.  
Three measurements were obtained at 
the beginning of incubation (time zero, T0) 
and 48h post-incubation for compound-free 
(C) and tested (T) cells. Cell proliferation was 
determined according to the equation 
100x[(T-T0)/C-T0], for T0<T≤ C, aŶd ϭϬϬǆ[;T-
T0)/T0], for T≤T0 . The concentration-response 
curve for each cell line was plotted and, from 
these curves, GI50 (concentration causing 50% 
growth inhibition) and TGI (concentration 
that promotes total growth inhibition) were 
determined by means of non-linear 
regression analysis using Origin 8.0 
software.10,11 
 
2.2.2. Antioedematogenic assay 
 
Borneol and its ester derivatives (1-8) 
were submitted to the antioedematogenic 
bioassay. This assay was conducted at the 
Laboratory of Physiology, Universidade 
Federal de Alfenas (UNIFAL, MG, Brazil). To
Silva, A. T. M. et al. 
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perform the anti-inflammatory assay (paw 
edema induced by carrageenan), borneol and 
its ester derivatives were suspended in 
carboxymethylcellulose solution (CMC, 0.5% 
w/V). The CMC was only used as thickener, 
since borneol esters are not water soluble 
and to avoid use organic solvents that might 
cause other type of damage to animals. 
Indomethacin solubilized in Tris buffer and 
saline in 1:1 ratio was used as positive control 
and CMC as negative control.12 
The animals used were adult male Swiss 
mice (25-35 g), which were obtained from 
the UNIFAL vivarium (UNIFAL Ethics 
Committee, protocol 488/2013). They were 
treated with commercial feed and water ad 
libitum, guaranteed its adaptation for 7 days 
at room temperature of 23 ± 2 °C with 12 h 
dark/light cycle in the appropriate 
polypropylene maintenance cycle boxes. 
They were deprived of food for 12 h prior to 
the experiment and at the end of the 
experiments the animals were sacrificed by 
halothane inhalation. 
Evaluation of the anti-inflammatory 
activity via paw edema test was induced by 
injection of 40 µL of carrageenan (2% w V-1) 
solubilized in sterile saline and administered 
into the subplantar region of the right hind 
paw of male mice (n = 8). One hour before 
injection of carrageenan, the animals were 
treated with the samples (oral via) at doses 
of 20 mg kg-1, or indomethacin (10 mg kg-1), 
or CMC vehicle (10 mL kg-1). The volume of 
the right paw of the animal was determined 
by immersing the tibio-tarsal region using a 
plethysmometer before carrageenan 
administration and one, two, three and four 
hours after receiving the carrageenan.13 
Results were processed using GraphPad® 
5.0 software to determine mean ± standard 
error of mean (SEM). Analysis of variance met 
assumptions of the method followed by 
Scott-Knott multiple comparisons test was 
conducted. Significant results were assumed 
for p<0.05 in all calculations. To facilitate 
comparisons among the tested samples, the 
results were expressed as % of oedema 
inhibition. 
 
3. Results and discussion 
 
3.1. Synthesis  
 
The structures and general synthesis of 
borneol ester derivatives are illustrated in 
Fig. 1.  Eight borneol analogs were obtained 
by two different methods. In all cases, 
DIC/DMAP method furnished high yields (54 
to 84%). The SOCl2 method also produced 
compounds 1-8, but the yields were 
moderate (7 to 44%). The compounds 1-5 
and 8 were news. All the esters were 
characterized by infrared (ATR), 1H and 13C 
NMR spectra. Assignments of the signals are 
based on the chemical shifts and intensity 
patterns. The structures of the compounds 1-
8 were confirmed by the presence of an 
intense absorption at 1708–1774 cm-1 that is 
characteristic of a carbonyl ester group. 1H 
and 13C NMR spectra of all the compounds 
were obtained and the presence of signals 
between H 4.85–5.27 ppm (H-2) and C 
164.7–174.3 ppm (C=O), respectively, 
confirmed the achievement of expected 
borneol esters. 
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Figure 1. Synthesis of borneol ester derivatives 
 
3.2. Characterization 
 
 (1S,2R,4S)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl hexanoate 
(1): yield: 62% by DIC/DMAP and 36% by 
SOCl2; clear oil; IR (ATR, cm
-1): 1160, 1175, 
1782, 2873, 2954; 1H RMN (200 MHz, CDCl3) 
H (ppm): 0.83 (s, 3H), 0.87 (s, 3H), 0.91-0.93 
(m, 6H), 0.99 (d, J= 3.4 Hz, 1H), 1.16-1.35 (m, 
6H), 1.56-1.78 (m, 4H), 1.87-2.01 (m, 1H), 
2.27-2.43 (m, 3H), 4.85-4.92 (ddd, J1= 2.2 Hz, 
J2= 3.4 Hz, J3= 10.0 Hz, 1H); 
13C NMR (50 MHz, 
CDCl3Ϳ δĐ ;ppŵͿ: ϭϯ.ϱ ;CH3), 13.9 (CH3), 18.8 
(CH3), 19.7 (CH3), 22.3 (CH2), 24.8 (CH2), 27.1 
(CH2), 28.0 (CH2), 31.3 (CH2), 34.7 (CH2), 36.8 
(CH2), 44.9 (CH), 47.7 (C), 48.7 (C), 79.5 (CH), 
174.2 (CO).      
 
 (1S,2R,4S)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl octanoate 
(2): yield: 79% by DIC/DMAP and 44% by 
SOCl2; clear oil; IR (ATR, cm
-1): 1160, 1175, 
1782, 2873, 2954; 1H RMN (200 MHz, CDCl3) 
H (ppm): 0.83 (s, 3H), 0.87-0.91 (m, 9H), 0.98 
(d, J= 3.4 Hz, 1H), 1.29 (br s, 10H), 1.60-1.76 
(m, 4H), 1.87-2.01 (m, 1H), 2.27-2.43 (m, 3H), 
4.85-4.92 (m, 1H); 13C NMR (50 MHz, CDCl3) 
δĐ ;ppŵͿ: ϭϯ.ϱ ;CH3), 14.1 (CH3), 18.9 (CH3), 
19.7 (CH3), 22.6 (CH2), 25.2 (CH2), 27.1 (CH2), 
28.1 (CH2), 29.0 (CH2), 29.1 (CH2), 31.7 (CH2), 
34.8 (CH2), 36.8 (CH2), 44.9 (CH), 47.8 (C), 
48.7 (C), 79.6 (CH), 174.3 (CO).        
 
 (1S,2R,4S)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl myristate 
(3): yield: 82% by DIC/DMAP and 17% by 
SOCl2; clear oil; IR (ATR, cm
-1): 1159, 1177, 
1784, 2853, 2923; 1H RMN (200 MHz, CDCl3) 
H (ppm): 0.83 (s, 3H), 0.87-0.91 (m, 9H), 0.98 
(d, J= 3.4 Hz, 1H), 1.26 (br s, 22H), 1.61-1.69 
(m, 4H), 1.87-2.01 (m, 1H), 2.27-2.43 (m, 3H), 
4.85-4.92 (m, 1H); 13C NMR (50 MHz, CDCl3) 
δĐ ;ppŵͿ: ϭϯ.ϱ ;CH3), 14.1 (CH3), 18.8 (CH3), 
19.7 (CH3), 22.7 (CH2), 25.1 (CH2), 27.1 (CH2), 
28.0 (CH2), 29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 
29.5 (CH2), 29.6 (4CH2), 31.9 (CH2), 34.7 (CH2), 
36.8 (CH2), 44.9 (CH), 47.7 (C), 48.7 (C), 79.5 
(CH), 174.2 (CO). 
 
 (1S,2R,4S)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl palmitate 
(4): yield: 73% by DIC/DMAP and 36% by 
SOCl2; clear oil; IR (ATR, cm
-1): 1159, 1177, 
1734, 2853, 2922; 1H RMN (200 MHz, CDCl3) 
H (ppm): 0.83 (s, 3H), 0.87-0.90 (m, 9H), 0.98 
(d, J= 3.4 Hz, 1H), 1.26 (br s, 26H), 1.60-1.69 
(m, 4H), 1.87-2.00 (m, 1H), 2.27-2.43 (m, 3H), 
4.85-4.92 (ddd, J1= 2.0 Hz, J2= 3.0 Hz, J3= 10.0 
Hz, 1H); 13C NMR (50 MHz, CDCl3Ϳ δĐ ;ppŵͿ: 
13.5 (CH3), 14.1 (CH3), 18.8 (CH3), 19.7 (CH3), 
22.7 (CH2), 25.1 (CH2), 27.1 (CH2), 28.0 (CH2), 
29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 
29.6 (CH2), 29.7 (5CH2), 31.9 (CH2), 34.7 (CH2), 
36.8 (CH2), 44.9 (CH), 47.7 (C), 48.7 (C), 79.5 
(CH), 174.2 (CO). 
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 (1S,2R,4S)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl stearate 
(5): yield: 65% by DIC/DMAP and 41% by 
SOCl2; clear oil; IR (ATR, cm
-1): 1159, 1175, 
1734, 2852, 2922; 1H RMN (200 MHz, CDCl3) 
H (ppm): 0.83 (s, 3H), 0.87-0.91 (m, 9H), 0.98 
(d, J= 3.4 Hz, 1H), 1.26 (br s, 30H), 1.59-1.76 
(m, 4H), 1.87-2.01 (m, 1H), 2.27-2.43 (m, 3H), 
4.85-4.92 (ddd, J1= 2.2 Hz, J2= 3.4 Hz, J3= 9.8 
Hz, 1H); 13C NMR (50 MHz, CDCl3Ϳ δĐ ;ppŵͿ: 
13.5 (CH3), 14.1 (CH3), 18.8 (CH3), 19.7 (CH3), 
22.7 (CH2), 25.1 (CH2), 27.1 (CH2), 28.0 (CH2), 
29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 
29.7 (8CH2), 31.9 (CH2), 34.7 (CH2), 36.8 (CH2), 
44.9 (CH), 47.7 (C), 48.7 (C), 79.5 (CH), 174.2 
(CO).  
  
 (1S,2R,4S)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl 3,4,5-
trimethoxybenzoate (6): yield: 54% by 
DIC/DMAP and 35% by SOCl2; white solid; 
m.p. 91-93 °C; IR (ATR, cm-1): 767, 873, 1122, 
1228, 1708, 2836, 2952; 1H RMN (200 MHz, 
CDCl3) H (ppm): 0.92 (s, 6H), 0.98 (s, 3H), 
1.12 (d, J= 13.6 Hz, 1H), 1.26-1.47 (m, 2H), 
1.75-1.81 (m, 2H), 2.05-2.16 (m, 1H), 2.42-
2.54 (m, 1H), 3.92 (s, 9H), 5.07-5.12 (m, 1H), 
7.32 (s, 2H); 13C NMR (50 MHz, CDCl3Ϳ δĐ 
(ppm): 13.6 (CH3), 18.9 (CH3), 19.7 (CH3), 27.4 
(CH2), 28.0 (CH2), 36.9 (CH2), 44.9 (CH), 47.8 
(C), 49.1 (C), 56.2 (2CH3), 60.9 (CH3), 80.6 
(CH), 106.7 (2CH), 125.9 (C), 142 (C), 152.9 
(2C), 166.4 (CO). 13C NMR spectral data are in 
accordance with data reported in the 
literature.5  
  
 (1S,2R,4S)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl benzoate 
(7): yield: 59% by DIC/DMAP and 26% by 
SOCl2; clear oil; IR (ATR, cm
-1): 708, 978, 1112, 
1270, 1451, 1714, 2879, 2953 cm-1; 1H RMN 
(200 MHz, CDCl3) H (ppm): 0.92 (s, 6H), 0.97 
(s, 3H), 1.08-1.17 (dd, J1= 3.4 Hz, J2= 13.6 Hz, 
1H), 1.27-1.46 (m, 2H), 1.74-1.86 (m, 2H), 
2.07-2.21 (m, 1H), 2.40-2.56 (m, 1H), 5.08-
5.16 (ddd, J1= 2.0 Hz, J2= 3.0 Hz, J3= 9.8 Hz, 
1H), 7.41-7.60 (m, 3H), 8.07 (d, J= 6.8 Hz, 2H); 
13C NMR (50 MHz, CDCl3Ϳ δĐ ;ppŵͿ: ϭϯ.ϲ 
(CH3), 18.9 (CH3), 19.7 (CH3), 27.4 (CH2), 28.1 
(CH2), 36.9 (CH2), 44.9 (CH), 47.8 (C), 49.1 (C), 
80.5 (CH), 128.3 (2CH), 129.5 (2CH), 130.8 
(C), 132.7 (CH), 166.8 (CO). 13C NMR spectral 
data are in accordance with data reported in 
the literature.5  
 
 (1S,2R,4S)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl 3,5-
dinitrobenzoate (8): yield: 84% by DIC/DMAP 
and 7% by SOCl2; white solid; m.p. 145-146 
°C; IR (ATR, cm-1): 718, 719, 822, 913, 1343, 
1541, 1723, 2879, 2956; 1H RMN (200 MHz, 
CDCl3) H (ppm): 0.95 (s, 6H), 0.99 (s, 3H), 
1.12-1.21 (dd, J1= 3.4 Hz, J2= 13.8 Hz, 1H), 
1.36-1.58 (m, 2H), 1.80-1.88 (m, 2H), 2.01-
2.14 (m, 1H), 2.46-2.62 (m, 1H), 5.20-5.27 (m, 
1H), 9.15 (d, J= 2.0 Hz, 2H), 9.23 (t, J= 2.1 Hz, 
1H); 13C NMR (50 MHz, CDCl3Ϳ δĐ ;ppŵͿ: ϭϯ.ϲ 
(CH3), 18.8 (CH3), 19.7 (CH3), 27.4 (CH2), 28 
(CH2), 36.7 (CH2), 44.8 (CH), 48.1 (C), 49.2 (C), 
83.1 (CH), 129.3 (2CH), 122.2 (CH), 134.5 (C), 
148.6 (2C), 162.7 (CO).  
 
3.3. Biological activities 
 
3.3.1. Antiproliferative assay 
 
In vitro antiproliferative property of 
borneol and its esters 1-8 was investigated in 
seven human tumor cell lines [breast (MCF-
7), ovarian (NCI-ADR/RES, OVCAR-03), renal 
(786-0), colon (HT-29) and leukemia (K-562)] 
and one human normal cell line (HaCat, 
human keratinocytes). Borneol and its 
derivatives (1-8) were assayed in 
concentrations of 0.25-ϮϱϬ μg/ŵL aŶd 
doxorubicin (DOX, 0.25-ϮϱϬ μg/ŵLͿ ǁas used 
as positive control. Cell proliferation was 
determined by spectrophotometric 
measurements using sulforhodamine B as a 
protein-binding. An effective concentration, 
eliciting 50% growth inhibition (GI50) was 
determined after 48 h of cell treatment (see 
Table 1). 
Compounds 3, 4, 5 and 8 do not present 
relevant effect against any of the cell lines 
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assayed (GI50>ϮϱϬ μg/ŵLͿ. These ĐoŵpouŶds 
had only cytostatic activities against all cell 
lines in the concentrations studied. The 
borneol derivatives 2, 6 and 7 were more 
selective against K562; however, compoud 7 
was 9-fold more potent to cancer cell line 
(K562) than human normal cell (HaCat). In 
fact, the bornyl ester 6 was the most potent 
ester derivative for all cell lines evaluated. 
Notably, the compound 6 was 2.4-fold more 
potent than the reference drug DOX in 
inhibiting the growth of adryamycin-resistant 
ovarian (NCI-ADR/RES) and less selective than 
DOX to human normal cell (HaCat). 
 
Table 1. Antiproliferative activity (GI50, μg/ŵLͿ of ďorŶeol aŶd its ester deriǀatiǀes ;1-8) on 
human cell lines 
Cell linesa DOXb 
Borne
ol 
1 2 3 4 5 6 7 8 
MCF-7 0.044 >250 76.4 29.2 >250 >250 >250 18.1 25.3 >250 
NCI-
ADR/RES 
6.7 >250 250 25.7 >250 >250 >250 2.8 26.1 >250 
786-0 0.092 >250 >250 29.4 >250 >250 >250 3.1 25.3 >250 
OVCAR-3 0.27 5.3 19.7 25.4 >250 >250 >250 3.0 26.6 >250 
HT29 0.26 111.5 >250 
108.
4 
>250 >250 >250 8.5 12.1 >250 
K562 0.31 83.7 10.2 9.5 >250 >250 >250 2.6 2.8 >250 
HaCat 0.040 >250 17.0 26.6 >250 >250 >250 4.8 25.9 >250 
aTumor cell lines: MCF-7 (mammary); NCI-ADR/RES (drug resistant ovary); 786-0 (kidney); 
OVCAR-3 (ovary); HT-29 (colon); K562 (leukemia). Normal cell lines: HaCat (immortalized 
keratinocytes); bDoxorubicin: positive control 
 
The percentage values for the growth 
inhibition of the cell proliferation for the 
three most active compounds, at four 
different concentrations are listed in the 
Table 2. Compound 2, 6 and 7 presented low 
cell growth inhibition at 0.25 and 2.5 µg/mL. 
However, in the concentration of 25 µg/mL, 
compound 6 showed relevant cytostatic 
activity for MCF-7 and OVCAR-3 and low 
cytotoxic activity for 786-0. In the same 
concentration, 2 and 7 present lower 
cytostatic activity for all cell lines. 
Compounds 2, 6 and 7 were cytotoxic to 
MCF-7, NCI-ADR/RES, 786-0, OVCAR-3, HaCat 
Đell liŶes ǁheŶ used at ϮϱϬ μg/ŵL. OŶlǇ the 
compound 7 was cytostatic against HT29 at 
ϮϱϬ μg/ŵL. 
Comparing activity of borneol and 
compound 7 against NCI-ADR/RES, MCF-7 
and 786-0 cells, borneol was inactive 
(GI50>ϮϱϬ μg/ŵLͿ. IŶ this Đase, the 
introduction of phenyl ring increased the 
antiproliferative activity 4-fold. The 
antiproliferative activity results of the 
compounds 6 and 7, allows inferring that the 
presence of phenyl group contributes to the 
action against the cell growth. Furthermore, 
the presence of electron-donating groups in 
compound 6, methoxyl substituents, suggests 
an improvement of the antiproliferative 
activity in up to 9-fold. 
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Table 2. Antiproliferative activity of 2, 6 and 7 on human cell lines as percentage of cell 
growth  
 Cell lines 
2 (µg/mL)  6 (µg/mL)  7 (µg/mL) 
0.25 2.5 25 250 0.25 2.5 25 250 0.25 2.5 25 250 
 MCF-7 13 18 20 -81 21 27 89 -65 15 19 48 -82 
 
NCI-
ADR/RES 
22 25 25 -86 24 40 83 -11 20 35 42 -88 
 786-0 14 20 20 -92 30 35 -2 -64 28 30 48 -90 
 OVCAR-3 30 39 47 -96 31 35 90 -100 15 27 38 -94 
 HT29 14 24 27 63 21 27 65 90 18 25 52 -4 
 K562 27 34 45 95 31 41 76 84 35 39 67 97 
 HaCat 24 28 36 -100 25 27 82 -100 22 26 42 -75 
 aTumor cell lines: MCF-7 (mammary); NCI-ADR/RES (drug resistant ovary); 786-0 (kidney); 
OVCAR-3 (ovary); HT-29 (colon); K562 (leukemia). Normal cell lines: HaCat (immortalized 
keratinocytes); bDoxorubicin: positive control. 
 
3.3.2. Antioedematogenic assay 
 
This assay demonstrates anti-
inflammatory effect of borneol esters in an 
experimental model of acute inflammation 
induced by carrageenan. Carrageenan is a 
polysaccharide present in red algae 
Rhodophyceae widely used to induce acute 
inflammatory response in experimental 
animals, since it induces the release of 
various inflammatory mediators such as 
histamine, bradykinin, prostaglandin, and 
superoxide anions.14 The use of carrageenan 
as irritant for inducing inflammation in rat 
paw was introduced by Winter et al.,15 
making it one of the most popular methods 
for drug testing and evaluation of novel anti-
inflammatory therapies.16 
Previous work shows carrageenan 
promoting a long-lasting inflammatory 
response in two phases when injected into 
rat paw. The first step results in a rapid 
production of various inflammatory 
mediators such as histamine, serotonin, and 
bradykinin. The second phase occurs with the 
release of prostaglandins and nitric oxide, 
with a peak at the third hour produced by 
inducible isoforms of cyclooxygenase (COX-2) 
and nitric oxide synthase (iNOS), 
respectively.17 Thus, antioedematogenic 
study was conducted during four hours 
aiming to understand how the borneol and 
its ester derivatives could act in the 
inflammatory process. 
Table 3 shows paw volumes followed by 
the percent inhibition of borneol esters (1-8) 
and indomethacin (positive control) in 
carrageenan-induced paw oedema. 
Indomethacin treatment at a dose of 10 mg 
kg−1 throughout the experimental period 
significantly inhibited hind paw swelling 
(p<0.05), with maximal inhibition of 53% and 
maximal effect after 4 h. 
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Table 3. Antioedematogenic activity induced by borneol and its ester derivatives (1-8) 
 
The means followed by the same letter do not differ significantly by the Scott-Knott test 
(p<0.05). 
 
At the first hour, borneol ester derivatives 
(1-8) reduced the oedematogenic process 
(from 34% to 47%), while indomethacin 
inhibited 39%. In the second hour, 
compounds 2 (49%), 3 (41%), 7 (63%), 8 
(43%) and indomethacin (46%) were more 
effective in inhibiting the inflammatory 
process. At the third hour, compounds 4 
(44%), 5 (43%), 7 (41%) and positive control 
(39%) were capable of reducing the oedema. 
At the fourth hour only compounds 4 (47%), 
7 (63%) and indomethacin (53%) exhibited a 
relevant inhibitory effect.  
Borneol and compound 6 did not inhibit 
inflammatory process in any time analyzed. 
However, the hydrophobic chain esters 
(compounds 1-5) have reduced the oedema 
with very similar inhibitory percentages, 
indicating that chain length did not influence 
their anti-inflammatory property. Compound 
7 was effective in inhibiting different stages 
of inflammation evaluated (1 h: 49%; 2 h: 
63%; 3 h: 41% and 4 h: 63%) and presented 
inhibition values greater than the positive 
control. The oral treatment with compound 7 
was effective in reducing the oedematogenic 
response evoked by carageenan in two 
phases. This reduction may be caused by 
inhibition of intracellular signalling pathways 
involved in mediating the inflammatory 
response. 
Anti-inflammatory activity is a known 
property of terpenes.18 To this biological 
effect have been attributed to different 
mechanisms of action such as: inhibition of 
elastase, inhibition of cyclooxygenase and 
lipoxygenase activities, and inhibition of 
complement activity, probably via inhibition 
of C3-convertase of the classical complement 
pathway.19 
 
4. Conclusion 
 
Eight borneol ester derivatives (1-8) were 
synthesized with high yields using the 
DIC/DMAP method and subjected to 
antiproliferative and antioedematogenic 
evaluation. Compounds 2, 6 and 7 showed a 
pronounced cytostatic activity against all cell 
lines assayed, revealing to be promising 
models for the development of alternative 
drugs that may be used in the treatment of 
Treatment Paw volume in mL (% of oedema inhibition) 
1st hour 2nd hour 3rd hour 4th hour 
Vehicle 0.049±0.004a 0.058±0.007b 0.067±0.006b 0.065±0.010ª 
Borneol 0.038±0.005a (23) 0.051±0.005b 
(12) 
0.055±0.006a 
(18) 
0.055±0.004a (15) 
1 0.027±0.007a (45) 0.046±0.007b 
(20) 
0.049±0.006a 
(28) 
0.053±0.007a (18) 
2 0.026±0.006a (47) 0.029± .006a 
(49) 
0.041±0.005a 
(39) 
0.043±0.05a (33) 
3 0.026±0.005a (47) 0.034±0.006a 
(41) 
0.051±0.003a 
(24) 
0.046±0.005a (29) 
4 0.029±0.007a (41) 0.038±0.007a 
(34) 
0.037±0.009a 
(44) 
0.034±0.010a (47) 
5 0.028±0.010a (43) 0.052±0.010b (9) 0.038±0.008a 
(43) 
0.053±0.009a (18) 
6 0.032±0.004a (34) 0.058±0.008b (0) 0.065±0.009b 
(4) 
0.049±0.010a (25) 
7 0.025±0.007a (49) 0.022±0.005a 
(63) 
0.040±0.007a 
(41) 
0.024±0.004a (63) 
8 0.031±0.005a (36) 0.033±0.006a 
(43) 
0.048±0.006a 
(29) 
0.042±0.008a (35) 
Indomethacin 0.030±0.006a (39) 0.031±0.005a 
(46) 
0.041±0.004a 
(39) 
0.031±0.008a (53) 
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cancer. Moreover, compound 7 showed 
potential antioedematogenic activity and 
could be useful models to assist the 
development of new anti-inflammatory 
drugs. 
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